收费全文 | 15705篇 |
免费 | 1018篇 |
国内免费 | 144篇 |
耳鼻咽喉 | 251篇 |
儿科学 | 181篇 |
妇产科学 | 214篇 |
基础医学 | 2412篇 |
口腔科学 | 420篇 |
临床医学 | 1105篇 |
内科学 | 3061篇 |
皮肤病学 | 690篇 |
神经病学 | 1011篇 |
特种医学 | 847篇 |
外科学 | 2342篇 |
综合类 | 93篇 |
一般理论 | 3篇 |
预防医学 | 681篇 |
眼科学 | 434篇 |
药学 | 1368篇 |
中国医学 | 218篇 |
肿瘤学 | 1536篇 |
2024年 | 16篇 |
2023年 | 130篇 |
2022年 | 357篇 |
2021年 | 595篇 |
2020年 | 263篇 |
2019年 | 408篇 |
2018年 | 501篇 |
2017年 | 388篇 |
2016年 | 590篇 |
2015年 | 756篇 |
2014年 | 906篇 |
2013年 | 964篇 |
2012年 | 1471篇 |
2011年 | 1342篇 |
2010年 | 781篇 |
2009年 | 659篇 |
2008年 | 940篇 |
2007年 | 837篇 |
2006年 | 766篇 |
2005年 | 745篇 |
2004年 | 612篇 |
2003年 | 490篇 |
2002年 | 426篇 |
2001年 | 374篇 |
2000年 | 302篇 |
1999年 | 226篇 |
1998年 | 111篇 |
1997年 | 85篇 |
1996年 | 61篇 |
1995年 | 70篇 |
1994年 | 58篇 |
1993年 | 47篇 |
1992年 | 105篇 |
1991年 | 71篇 |
1990年 | 55篇 |
1989年 | 49篇 |
1988年 | 50篇 |
1987年 | 36篇 |
1986年 | 32篇 |
1985年 | 31篇 |
1984年 | 15篇 |
1983年 | 22篇 |
1981年 | 8篇 |
1980年 | 13篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1976年 | 9篇 |
1975年 | 8篇 |
1973年 | 11篇 |
1968年 | 9篇 |
Etodolac is a nonsteroidal anti-inflammatory drug with selective cyclooxygenase-2 inhibition to treat pain and inflammation associated with osteoarthritis in humans and dogs. The aim of the study was to investigate the pharmacokinetics of etodolac following single oral administration of 200?mg to 10 healthy beagle dogs.
The plasma concentrations of etodolac were detected using liquid chromatography-tandem mass spectrometry. Pharmacokinetic analysis was conducted using the noncompartmental method and modeling approaches.
Etodolac was rapidly absorbed (Tmax?=?0.85?h, Ka?=?1.49?h?1) and slowly eliminated (T1/2?=?39.55?h) following oral administration to the dogs. A two-compartment pharmacokinetic model with first-order absorption and elimination rate constants was successfully explained for the pharmacokinetic aspects of etodolac in dogs. From a Monte Carlo simulation (1000 repetitions), the accumulation index and AUCτ at steady state were predicted as 1.60 [90% confidence intervals (CI), 1.24–2.81] and 408.18?ng·hr/mL [90% CI, 271.26–590.58?ng·hr/mL], respectively.
This study will help to enact a more accurate optimal dosing regimen of etodolac in dogs with osteoarthritis, and may be useful in developing a novel formulation of etodolac for human in the future.
Purpose
Work-related eye injuries have been reported with a variety of epidemiologic and clinical characteristics. We aimed to identify epidemiologic characteristics of work-related eye injuries and risk factors associated with severe injury in a large metropolitan city. 相似文献Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)